Variation at FCGR2A and functionally related genes is associated with the response to anti-TNF therapy in rheumatoid arthritis

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Avila Pedretti, Gabriela ^a   Tornero, Jesús ^b   Fernández Nebro, Antonio ^c   Blanco, Francisco ^d   González Alvaro, Isidoro ^e   Cañete, Juan D ^f   Maymó, Joan ^g   Alperiz, Mercedes ^h   Fernández Gutiérrez, Benjamín ⁱ   Olivé, Alex ^j   Corominas, Héctor ^k   Erra, Alba ^l   Aterido, Adrià ^a   Lasanta, María López ^a   Tortosa, Raül ^a   Julià, Antonio ^a   Marsal, Sara ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d UNIVERSITY OF A CORUÑA   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^k Moises Broggi Hospital Sant Joan d'Espì   (Spain)

^l Hospital Sant Rafael   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; FC RECEPTOR; FCGR2A PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ADULT; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CELLS BY BODY ANATOMY; COHORT ANALYSIS; CONTROLLED STUDY; DHX32 GENE; FCGR2A GENE; FEMALE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; RGS12 GENE; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SPANIARD; SYNOVIAL FLUID; TREATMENT RESPONSE; VALIDATION PROCESS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DRUG EFFECTS; GENETICS; IMMUNOLOGY; TREATMENT OUTCOME;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MACROPHAGES; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG; SYNOVIAL FLUID; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929483872     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122088     Document Type: Article

References (51)

1. Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LHD, Funovits J, et al. (2011) American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum 63: 573-586. doi: 10.1002/art.30129 PMID: 21294106
2. Smolen JS, Aletaha D (2006) What should be our treatment goal in rheumatoid arthritis today? Clin Exp Rheumatol 24 Suppl 43: S-7-13. PMID: 17083756
3. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, et al. (2011) Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 70: 266-271. doi: 10.1136/ard.2010.132134 PMID: 21097801
4. van den Broek M, Visser K, Allaart CF, Huizinga TWJ (2013) Personalized medicine: predicting responses to therapy in patients with RA. Curr Opin Pharmacol 13: 463-469. doi: 10.1016/j.coph.2013. 03.006 PMID: 23578763
5. Emery P, Dorner T (2011) Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 70: 2063-2070. doi: 10.1136/ard.2010.148015 PMID: 22039166
6. Burska AN, Roget K, Blits M, Soto Gomez L, van de Loo F, Hazelwood LD, et al. (2014) Gene expression analysis in RA: towards personalized medicine. Pharmacogenomics J 14: 93-106. doi: 10.1038/ tpj.2013.48 PMID: 24589910
7. Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, et al. (2013) Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet 9: e1003394. doi: 10.1371/journal.pgen.1003394 PMID: 23555300
8. Krintel SB, Palermo G, Johansen JS, Germer S, Essioux L, Benayed R, et al. (2012) Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet Genomics 22: 577-589. doi: 10.1097/FPC. 0b013e3283544043 PMID: 22569225
9. Acosta-Colman I, Palau N, Tornero J, Fernandez-Nebro A, Blanco F, Gonzalez-Alvaro I, et al. (2013) GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics 14: 727-734. doi: 10.2217/pgs.13.60 PMID: 23651021
10. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN (2014) The function of Fcgamma receptors in dendritic cells and macrophages. Nat Rev Immunol 14: 94-108. doi: 110.1038/nri3582. Epub 2014 Jan 1021. PMID: 24445665
11. Montes A, Perez-Pampin E, Narvaez J, Canete JD, Navarro-Sarabia F, Moreira V, et al. (2014) Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenet Genomics 24: 238-245. doi: 10.1097/FPC.0000000000000042 PMID: 24667440
12. Ivan E, Colovai AI (2006) Human Fc receptors: critical targets in the treatment of autoimmune diseases and transplant rejections. Hum Immunol 67: 479-491. PMID: 16829303
13. Siberil S, Dutertre CA, Boix C, Bonnin E, Menez R, Stura E, et al. (2006)Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences. Immunol Lett 106: 111-118. PMID: 16797726
14. Ravetch JV, Lanier LL (2000) Immune inhibitory receptors. Science 290: 84-89. PMID: 11021804
15. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8: 34-47. PMID: 18064051
16. ZhangW, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, et al. (2007) FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25: 3712-3718. PMID: 17704420
17. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26: 1789-1796. doi: 10.1200/JCO.2007.14. 8957 PMID: 18347005
18. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21: 3940-3947. PMID: 12975461
19. Paiva M, Marques H, Martins A, Ferreira P, Catarino R, Medeiros R (2008) FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients. Cancer Genet Cytogenet 183: 35-40. doi: 10.1016/j.cancergencyto.2008.02.001 PMID: 18474295
20. Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, et al. (2009) Differences in binding and effector functions between classes of TNF antagonists. Cytokine 45: 124-131. doi: 10.1016/j.cyto. 2008.11.008 PMID: 19128982
21. Guilliams M, Bruhns P, Saeys Y, Hammad H, Lambrecht BN (2014) The function of Fcγ receptors in dendritic cells and macrophages. Nat Rev Immunol 14: 94-108. doi: 10.1038/nri3582 PMID: 24445665
22. Mimoto F, Kadono S, Katada H, Igawa T, Kamikawa T, Hattori K (2014) Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs. Mol Immunol 58: 132-138. doi: 10.1016/j.molimm.2013.11.017 PMID: 24334029
23. Dijstelbloem HM, van de Winkel JG, Kallenberg CG (2001) Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol 22: 510-516. PMID: 11525942
24. Bruhns P (2012) Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119: 5640-5649. doi: 5610.1182/blood-2012-5601-380121. Epub 382012 Apr 380125. PMID: 22535666
25. Canete JD, Suarez B, Hernandez MV, Sanmarti R, Rego I, Celis R, et al. (2009) Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis 68: 1547-1552. doi: 1510.1136/ard.2008.096982. Epub 092008 Oct 096917. PMID: 18930989
26. Montes A, Perez-Pampin E, Narvaez J, Canete JD, Navarro-Sarabia F, Moreira V, et al. (2014) Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenet Genomics 24: 238-245. doi: 10.1097/FPC.0000000000000042 PMID: 24667440
27. Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, et al. (2004) The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 50: 2750-2756. PMID: 15457442
28. Padyukov L, Seielstad M, Ong RT, Ding B, Ronnelid J, Seddighzadeh M, et al. (2011) A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 70: 259-265. doi: 210.1136/ard.2009.126821. Epub 122010 Dec 126814. PMID: 21156761
29. Kurreeman F, Liao K, Chibnik L, Hickey B, Stahl E, Gainer V, et al. (2011) Genetic basis of autoantibody positive and negative rheumatoid arthritis risk in a multi-ethnic cohort derived from electronic health records. Am J Hum Genet 88: 57-69. doi: 10.1016/j.ajhg.2010.1012.1007 PMID: 21211616
30. Bossini-Castillo L, de Kovel C, Kallberg H, van 't Slot R, Italiaander A, Coenen M, et al. (2014) A genome- wide association study of rheumatoid arthritis without antibodies against citrullinated peptides. Ann Rheum Dis 14: 2013-204591.
31. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324. PMID: 3358796
32. van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41: 1845-1850. PMID: 9778226
33. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL, et al. (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44-48. PMID: 7818570
34. Barrett T, Edgar R (2006) Gene expression omnibus: microarray data storage, submission, retrieval, and analysis. Methods Enzymol 411: 352-369. PMID: 16939800
35. Team RC (2013) R: A Language and Environment for Statistical Computing. ( R Foundation for Statistical Computing, Vienna, 2009). doi: 10.3758/s13428-013-0330-5 PMID: 23519455
36. Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, Handsaker RE, et al. (2012) An integrated map of genetic variation from 1, 092 human genomes. Nature 491: 56-65. doi: 10.1038/nature11632 PMID: 23128226
37. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265. Epub 2004 Aug 2005. PMID: 15297300
38. Zondervan KT, Cardon LR (2004) The complex interplay among factors that influence allelic association. Nat Rev Genet 5: 89-100. PMID: 14735120
39. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, et al. (2006) Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 116: 961-973. PMID: 16585962
40. Takai T (2002) Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2: 580-592. PMID: 12154377
41. Abdelhaleem M (2002) The novel helicase homologue DDX32 is down-regulated in acute lymphoblastic leukemia. Leuk Res 26: 945-954. PMID: 12163057
42. Alli Z, Chen Y, Abdul Wajid S, Al-Saud B, Abdelhaleem M (2007) A role for DHX32 in regulating T-cell apoptosis. Anticancer Res 27: 373-377. PMID: 17352256
43. Alli Z, Nam EH, Beimnet K, Abdelhaleem M (2005) The activation-induced expression of DHX32 in Jurkat T cells is specific and involves calcium and nuclear factor of activated T cells. Cell Immunol 237: 141-146. PMID: 16414036
44. Abdelhaleem M, Sun TH, Ho M (2005) DHX32 expression suggests a role in lymphocyte differentiation. Anticancer Res 25: 2645-2648. PMID: 16080506
45. Meylan E, Tschopp J (2006) Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell 22: 561-569. PMID: 16762830
46. Baccala R, Gonzalez-Quintial R, Lawson BR, Stern ME, Kono DH, Beutler B, et al. (2009) Sensors of the innate immune system: their mode of action. Nat Rev Rheumatol 5: 448-456. 410.1038/ nrrheum.2009.1136. Epub 2009 Jul 1014. doi: 10.1038/nrrheum.2009.136 PMID: 19597511
47. Narendra SC, Chalise JP, Hook N, MagnussonM (2014) Dendritic cells activated by double-stranded RNA induce arthritis via autocrine type I IFN signaling. J Leukoc Biol 95: 661-666. 610.1189/ jlb.0613320. Epub 0612013 Dec 0613324. doi: 10.1189/jlb.0613320 PMID: 24304616
48. Mitoma H, Hanabuchi S, Kim T, Bao M, Zhang Z, Sugimoto N, et al. (2013) The DHX33 RNA helicase senses cytosolic RNA and activates the NLRP3 inflammasome. Immunity 39: 123-135. 110.1016/j. immuni.2013.1007.1001. Epub 2013 Jul 1018. doi: 10.1016/j.immuni.2013.07.001 PMID: 23871209
49. Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S, et al. (2014) Evidence of NLRP3- inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis 73: 1202-1210. 1210.1136/annrheumdis-2013-203276. Epub 202013 May 203217. doi: 10.1136/ annrheumdis-2013-203276 PMID: 23687262
50. Yang S, Li YP (2007) RGS12 is essential for RANKL-evoked signaling for terminal differentiation of osteoclasts in vitro. J Bone Miner Res 22: 45-54. PMID: 17042716
51. Lundstrom E, Kallberg H, Alfredsson L, Klareskog L, Padyukov L (2009) Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. Arthritis Rheum 60: 1597-1603. 1510.1002/art.24572. doi: 10.1002/art.24572 PMID: 19479873